A BILL 
To incentivize low-cost drug options and generic competition, 
and to provide extensions for community health centers 
and the National Health Service Corps, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
04:40 May 29, 2019
H2700
2 
•HR 2700 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Lowering Prescription 
2
Drug Costs and Extending Community Health Centers 
3
and Other Public Health Priorities Act’’. 
4
SEC. 2. TABLE OF CONTENTS. 
5
The table of contents of this Act is as follows: 
6
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—LOWERING PRESCRIPTION DRUG COSTS 
Subtitle A—Bringing Low-Cost Options and Competition While Keeping 
Incentives for New Generics 
Sec. 101. Change conditions of first generic exclusivity to spur access and com-
petition. 
Subtitle B—Protecting Consumer Access to Generic Drugs 
Sec. 111. Unlawful agreements. 
Sec. 112. Notice and certification of agreements. 
Sec. 113. Forfeiture of 180-day exclusivity period. 
Sec. 114. Commission litigation authority. 
Sec. 115. Statute of limitations. 
Subtitle C—Creating and Restoring Equal Access to Equivalent Samples 
Sec. 121. Actions for delays of generic drugs and biosimilar biological products. 
Sec. 122. REMS approval process for subsequent filers. 
Sec. 123. Rule of construction. 
TITLE II—EXTENSION OF PUBLIC HEALTH PROGRAMS 
Sec. 201. Extension for community health centers, the National Health Service 
Corps, and teaching health centers that operate GME pro-
grams. 
Sec. 202. Extension for special diabetes programs. 
Sec. 203. Extension for family-to-family health information centers. 
Sec. 204. Extension for sexual risk avoidance education and personal responsi-
bility education. 
04:40 May 29, 2019
H2700
3 
•HR 2700 IH
TITLE I—LOWERING 
1
PRESCRIPTION DRUG COSTS 
2
Subtitle A—Bringing Low-Cost Op-
3
tions and Competition While 
4
Keeping 
Incentives 
for 
New 
5
Generics 
6
SEC. 101. CHANGE CONDITIONS OF FIRST GENERIC EXCLU-
7
SIVITY TO SPUR ACCESS AND COMPETITION. 
8
Section 505(j)(5)(B)(iv) of the Federal Food, Drug, 
9
and Cosmetic Act (21 U.S.C. 355(j)(5)(B)(iv)) is amend-
10
ed— 
11
(1) in subclause (I), by striking ‘‘180 days 
12
after’’ and all that follows through the period at the 
13
end and inserting the following: ‘‘180 days after the 
14
earlier of— 
15
‘‘(aa) the date of the first com-
16
mercial marketing of the drug (includ-
17
ing the commercial marketing of the 
18
listed drug) by any first applicant; or 
19
‘‘(bb) the applicable date speci-
20
fied in subclause (III).’’; and 
21
(2) by adding at the end the following new sub-
22
clause: 
23
‘‘(III) APPLICABLE DATE.—The appli-
24
cable date specified in this subclause, with 
25
04:40 May 29, 2019
H2700
4 
•HR 2700 IH
respect to an application for a drug de-
1
scribed in subclause (I), is the date on 
2
which each of the following conditions is 
3
first met: 
4
‘‘(aa) The approval of such an 
5
application could be made effective, 
6
but for the eligibility of a first appli-
7
cant for 180-day exclusivity under 
8
this clause. 
9
‘‘(bb) At least 30 months have 
10
passed since the date of submission of 
11
an application for the drug by at least 
12
one first applicant. 
13
‘‘(cc) Approval of an application 
14
for the drug submitted by at least one 
15
first applicant is not precluded under 
16
clause (iii). 
17
‘‘(dd) No application for the drug 
18
submitted by any first applicant is ap-
19
proved at the time the conditions 
20
under items (aa), (bb), and (cc) are 
21
all met, regardless of whether such an 
22
application 
is 
subsequently 
ap-
23
proved.’’. 
24
04:40 May 29, 2019
H2700
5 
•HR 2700 IH
Subtitle B—Protecting Consumer 
1
Access to Generic Drugs 
2
SEC. 111. UNLAWFUL AGREEMENTS. 
3
(a) AGREEMENTS PROHIBITED.—Subject to sub-
4
sections (b) and (c), it shall be unlawful for an NDA or 
5
BLA holder and a subsequent filer (or for two subsequent 
6
filers) to enter into, or carry out, an agreement resolving 
7
or settling a covered patent infringement claim on a final 
8
or interim basis if under such agreement— 
9
(1) a subsequent filer directly or indirectly re-
10
ceives from such holder (or in the case of such an 
11
agreement between two subsequent filers, the other 
12
subsequent filer) anything of value, including a li-
13
cense; and 
14
(2) the subsequent filer agrees to limit or fore-
15
go research on, or development, manufacturing, 
16
marketing, or sales, for any period of time, of the 
17
covered product that is the subject of the application 
18
described in subparagraph (A) or (B) of subsection 
19
(g)(8). 
20
(b) EXCLUSION.—It shall not be unlawful under sub-
21
section (a) if a party to an agreement described in such 
22
subsection demonstrates by clear and convincing evidence 
23
that the value described in subsection (a)(1) is compensa-
24
04:40 May 29, 2019
H2700
6 
•HR 2700 IH
tion solely for other goods or services that the subsequent 
1
filer has promised to provide. 
2
(c) LIMITATION.—Nothing in this section shall pro-
3
hibit an agreement resolving or settling a covered patent 
4
infringement claim in which the consideration granted by 
5
the NDA or BLA holder to the subsequent filer (or from 
6
one subsequent filer to another) as part of the resolution 
7
or settlement includes only one or more of the following: 
8
(1) The right to market the covered product 
9
that is the subject of the application described in 
10
subparagraph (A) or (B) of subsection (g)(8) in the 
11
United States before the expiration of— 
12
(A) any patent that is the basis of the cov-
13
ered patent infringement claim; or 
14
(B) any patent right or other statutory ex-
15
clusivity that would prevent the marketing of 
16
such covered product. 
17
(2) A payment for reasonable litigation ex-
18
penses not to exceed $7,500,000 in the aggregate. 
19
(3) A covenant not to sue on any claim that 
20
such covered product infringes a patent. 
21
(d) ENFORCEMENT BY FEDERAL TRADE COMMIS-
22
SION.— 
23
04:40 May 29, 2019
H2700
7 
•HR 2700 IH
(1) GENERAL APPLICATION.—The requirements 
1
of this section apply, according to their terms, to an 
2
NDA or BLA holder or subsequent filer that is— 
3
(A) a person, partnership, or corporation 
4
over which the Commission has authority pur-
5
suant to section 5(a)(2) of the Federal Trade 
6
Commission Act (15 U.S.C. 45(a)(2)); or 
7
(B) a person, partnership, or corporation 
8
over which the Commission would have author-
9
ity pursuant to such section but for the fact 
10
that such person, partnership, or corporation is 
11
not organized to carry on business for its own 
12
profit or that of its members. 
13
(2) UNFAIR OR DECEPTIVE ACTS OR PRACTICES 
14
ENFORCEMENT AUTHORITY.— 
15
(A) IN GENERAL.—A violation of this sec-
16
tion shall be treated as an unfair or deceptive 
17
act or practice in violation of section 5(a)(1) of 
18
the Federal Trade Commission Act (15 U.S.C. 
19
45(a)(1)). 
20
(B) POWERS OF COMMISSION.—Except as 
21
provided in subparagraph (C) and paragraphs 
22
(1)(B) and (3)— 
23
(i) the Commission shall enforce this 
24
section in the same manner, by the same 
25
04:40 May 29, 2019
H2700
8 
•HR 2700 IH
means, and with the same jurisdiction, 
1
powers, and duties as though all applicable 
2
terms and provisions of the Federal Trade 
3
Commission Act (15 U.S.C. 41 et seq.) 
4
were incorporated into and made a part of 
5
this section; and 
6
(ii) any NDA or BLA holder or subse-
7
quent filer that violates this section shall 
8
be subject to the penalties and entitled to 
9
the privileges and immunities provided in 
10
the Federal Trade Commission Act. 
11
(C) JUDICIAL REVIEW.—In the case of a 
12
cease and desist order issued by the Commis-
13
sion under section 5 of the Federal Trade Com-
14
mission Act (15 U.S.C. 45) for violation of this 
15
section, a party to such order may obtain judi-
16
cial review of such order as provided in such 
17
section 5, except that— 
18
(i) such review may only be obtained 
19
in— 
20
(I) the United States Court of 
21
Appeals for the District of Columbia 
22
Circuit; 
23
(II) the United States Court of 
24
Appeals for the circuit in which the 
25
04:40 May 29, 2019
H2700
9 
•HR 2700 IH
ultimate parent entity, as defined in 
1
section 801.1(a)(3) of title 16, Code 
2
of Federal Regulations, or any suc-
3
cessor thereto, of the NDA or BLA 
4
holder (if any such holder is a party 
5
to such order) is incorporated as of 
6
the date that the application described 
7
in subparagraph (A) or (B) of sub-
8
section (g)(8) or an approved applica-
9
tion that is deemed to be a license for 
10
a biological product under section 
11
351(k) of the Public Health Service 
12
Act (42 U.S.C. 262(k)) pursuant to 
13
section 7002(e)(4) of the Biologics 
14
Price Competition and Innovation Act 
15
of 2009 (Public Law 111–148; 124 
16
Stat. 817) is submitted to the Com-
17
missioner of Food and Drugs; or 
18
(III) the United States Court of 
19
Appeals for the circuit in which the 
20
ultimate parent entity, as so defined, 
21
of any subsequent filer that is a party 
22
to such order is incorporated as of the 
23
date that the application described in 
24
subparagraph (A) or (B) of subsection 
25
04:40 May 29, 2019
H2700
10 
•HR 2700 IH
(g)(8) is submitted to the Commis-
1
sioner of Food and Drugs; and 
2
(ii) the petition for review shall be 
3
filed in the court not later than 30 days 
4
after such order is served on the party 
5
seeking review. 
6
(3) ADDITIONAL ENFORCEMENT AUTHORITY.— 
7
(A) CIVIL
PENALTY.—The Commission 
8
may commence a civil action to recover a civil 
9
penalty in a district court of the United States 
10
against any NDA or BLA holder or subsequent 
11
filer that violates this section. 
12
(B) SPECIAL
RULE
FOR
RECOVERY
OF 
13
PENALTY
IF
CEASE
AND
DESIST
ORDER 
14
ISSUED.— 
15
(i) IN GENERAL.—If the Commission 
16
has issued a cease and desist order in a 
17
proceeding under section 5 of the Federal 
18
Trade Commission Act (15 U.S.C. 45) for 
19
violation of this section— 
20
(I) the Commission may com-
21
mence a civil action under subpara-
22
graph (A) to recover a civil penalty 
23
against any party to such order at 
24
any time before the expiration of the 
25
04:40 May 29, 2019
H2700
11 
•HR 2700 IH
1-year period beginning on the date 
1
on which such order becomes final 
2
under section 5(g) of such Act (15 
3
U.S.C. 45(g)); and 
4
(II) in such civil action, the find-
5
ings of the Commission as to the ma-
6
terial facts in such proceeding shall be 
7
conclusive, unless— 
8
(aa) the terms of such order 
9
expressly provide that the Com-
10
mission’s findings shall not be 
11
conclusive; or 
12
(bb) such order became final 
13
by reason of section 5(g)(1) of 
14
such Act (15 U.S.C. 45(g)(1)), in 
15
which case such findings shall be 
16
conclusive if supported by evi-
17
dence. 
18
(ii) RELATIONSHIP TO PENALTY FOR 
19
VIOLATION
OF
AN
ORDER.—The penalty 
20
provided in clause (i) for violation of this 
21
section is separate from and in addition to 
22
any penalty that may be incurred for viola-
23
tion of an order of the Commission under 
24
04:40 May 29, 2019
H2700
12 
•HR 2700 IH
section 5(l) of the Federal Trade Commis-
1
sion Act (15 U.S.C. 45(l)). 
2
(C) AMOUNT OF PENALTY.— 
3
(i) IN GENERAL.—The amount of a 
4
civil penalty imposed in a civil action under 
5
subparagraph (A) on a party to an agree-
6
ment described in subsection (a) shall be 
7
sufficient to deter violations of this section, 
8
but in no event greater than— 
9
(I) if such party is the NDA or 
10
BLA holder (or, in the case of an 
11
agreement between two subsequent fil-
12
ers, the subsequent filer who gave the 
13
value described in subsection (a)(1)), 
14
the greater of— 
15
(aa) 3 times the value re-
16
ceived by such NDA or BLA 
17
holder (or by such subsequent 
18
filer) that is reasonably attrib-
19
utable to the violation of this sec-
20
tion; or 
21
(bb) 3 times the value given 
22
to the subsequent filer (or to the 
23
other subsequent filer) reason-
24
04:40 May 29, 2019
H2700
13 
•HR 2700 IH
ably attributable to the violation 
1
of this section; and 
2
(II) if such party is the subse-
3
quent filer (or, in the case of an 
4
agreement between two subsequent fil-
5
ers, the subsequent filer who received 
6
the value described in subsection 
7
(a)(1)), 3 times the value received by 
8
such subsequent filer that is reason-
9
ably attributable to the violation of 
10
this section. 
11
(ii) FACTORS FOR CONSIDERATION.— 
12
In determining such amount, the court 
13
shall take into account— 
14
(I) the nature, circumstances, ex-
15
tent, and gravity of the violation; 
16
(II) with respect to the violator, 
17
the degree of culpability, any history 
18
of violations, the ability to pay, any 
19
effect on the ability to continue doing 
20
business, profits earned by the NDA 
21
or BLA holder (or, in the case of an 
22
agreement between two subsequent fil-
23
ers, the subsequent filer who gave the 
24
value described in subsection (a)(1)), 
25
04:40 May 29, 2019
H2700
14 
•HR 2700 IH
compensation received by the subse-
1
quent filer (or, in the case of an 
2
agreement between two subsequent fil-
3
ers, the subsequent filer who received 
4
the value described in subsection 
5
(a)(1)), and the amount of commerce 
6
affected; and 
7
(III) other matters that justice 
8
requires. 
9
(D) INJUNCTIONS AND OTHER EQUITABLE 
10
RELIEF.—In a civil action under subparagraph 
11
(A), the United States district courts are em-
12
powered to grant mandatory injunctions and 
13
such other and further equitable relief as they 
14
deem appropriate. 
15
(4) REMEDIES
IN
ADDITION.—Remedies pro-
16
vided in this subsection are in addition to, and not 
17
in lieu of, any other remedy provided by Federal 
18
law. 
19
(5) PRESERVATION OF AUTHORITY OF COMMIS-
20
SION.—Nothing in this section shall be construed to 
21
affect any authority of the Commission under any 
22
other provision of law. 
23
(e) FEDERAL TRADE COMMISSION RULEMAKING.— 
24
The Commission may, in its discretion, by rule promul-
25
04:40 May 29, 2019
H2700
15 
•HR 2700 IH
gated under section 553 of title 5, United States Code, 
1
exempt from this section certain agreements described in 
2
subsection (a) if the Commission finds such agreements 
3
to be in furtherance of market competition and for the 
4
benefit of consumers. 
5
(f) ANTITRUST LAWS.—Nothing in this section shall 
6
modify, impair, limit, or supersede the applicability of the 
7
antitrust laws as defined in subsection (a) of the first sec-
8
tion of the Clayton Act (15 U.S.C. 12(a)), and of section 
9
5 of the Federal Trade Commission Act (15 U.S.C. 45) 
10
to the extent that such section 5 applies to unfair methods 
11
of competition. Nothing in this section shall modify, im-
12
pair, limit, or supersede the right of a subsequent filer 
13
to assert claims or counterclaims against any person, 
14
under the antitrust laws or other laws relating to unfair 
15
competition. 
16
(g) DEFINITIONS.—In this section: 
17
(1) AGREEMENT
RESOLVING
OR
SETTLING
A 
18
COVERED
PATENT
INFRINGEMENT
CLAIM.—The 
19
term ‘‘agreement resolving or settling a covered pat-
20
ent infringement claim’’ means any agreement 
21
that— 
22
(A) resolves or settles a covered patent in-
23
fringement claim; or 
24
04:40 May 29, 2019
H2700
16 
•HR 2700 IH
(B) is contingent upon, provides for a con-
1
tingent condition for, or is otherwise related to 
2
the resolution or settlement of a covered patent 
3
infringement claim. 
4
(2) COMMISSION.—The term ‘‘Commission’’ 
5
means the Federal Trade Commission. 
6
(3) COVERED PATENT INFRINGEMENT CLAIM.— 
7
The term ‘‘covered patent infringement claim’’ 
8
means an allegation made by the NDA or BLA hold-
9
er to a subsequent filer (or, in the case of an agree-
10
ment between two subsequent filers, by one subse-
11
quent filer to another), whether or not included in 
12
a complaint filed with a court of law, that— 
13
(A) the submission of the application de-
14
scribed in subparagraph (A) or (B) of para-
15
graph (9), or the manufacture, use, offering for 
16
sale, sale, or importation into the United States 
17
of a covered product that is the subject of such 
18
an application— 
19
(i) in the case of an agreement be-
20
tween an NDA or BLA holder and a sub-
21
sequent filer, infringes any patent owned 
22
by, or exclusively licensed to, the NDA or 
23
BLA holder of the covered product; or 
24
04:40 May 29, 2019
H2700
17 
•HR 2700 IH
(ii) in the case of an agreement be-
1
tween two subsequent filers, infringes any 
2
patent owned by the subsequent filer; or 
3
(B) in the case of an agreement between 
4
an NDA or BLA holder and a subsequent filer, 
5
the covered product to be manufactured under 
6
such application uses a covered product as 
7
claimed in a published patent application. 
8
(4) COVERED
PRODUCT.—The term ‘‘covered 
9
product’’ means a drug (as defined in section 201(g) 
10
of the Federal Food, Drug, and Cosmetic Act (21 
11
U.S.C. 321(g))), including a biological product (as 
12
defined in section 351(i) of the Public Health Serv-
13
ice Act (42 U.S.C. 262(i)). 
14
(5) NDA OR BLA HOLDER.—The term ‘‘NDA 
15
or BLA holder’’ means— 
16
(A) the holder of— 
17
(i) an approved new drug application 
18
filed under section 505(b)(1) of the Fed-
19
eral Food, Drug, and Cosmetic Act (21 
20
U.S.C. 355(b)(1)) for a covered product; 
21
or 
22
(ii) a biologics license application filed 
23
under section 351(a) of the Public Health 
24
04:40 May 29, 2019
H2700
18 
•HR 2700 IH
Service Act (42 U.S.C. 262(a)) with re-
1
spect to a biological product; 
2
(B) a person owning or controlling enforce-
3
ment of the patent on— 
4
(i) the list published under section 
5
505(j)(7) of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 355(j)(7)) in con-
7
nection with the application described in 
8
subparagraph (A)(i); or 
9
(ii) any list published under section 
10
351 of the Public Health Service Act (42 
11
U.S.C. 262) comprised of patents associ-
12
ated with biologics license applications filed 
13
under section 351(a) of such Act (42 
14
U.S.C. 262(a)); or 
15
(C) the predecessors, subsidiaries, divi-
16
sions, groups, and affiliates controlled by, con-
17
trolling, or under common control with any en-
18
tity described in subparagraph (A) or (B) (such 
19
control to be presumed by direct or indirect 
20
share ownership of 50 percent or greater), as 
21
well as the licensees, licensors, successors, and 
22
assigns of each of the entities. 
23
04:40 May 29, 2019
H2700
19 
•HR 2700 IH
(6) PATENT.—The term ‘‘patent’’ means a pat-
1
ent issued by the United States Patent and Trade-
2
mark Office. 
3
(7) 
STATUTORY
EXCLUSIVITY.—The 
term 
4
‘‘statutory exclusivity’’ means those prohibitions on 
5
the submission or approval of drug applications 
6
under 
clauses 
(ii) 
through 
(iv) 
of 
section 
7
505(c)(3)(E) (5- and 3-year exclusivity), clauses (ii) 
8
through (iv) of section 505(j)(5)(F) (5-year and 3- 
9
year exclusivity), section 505(j)(5)(B)(iv) (180-day 
10
exclusivity), section 527 (orphan drug exclusivity), 
11
section 505A (pediatric exclusivity), or section 505E 
12
(qualified infectious disease product exclusivity) of 
13
the Federal Food, Drug, and Cosmetic Act (21 
14
U.S.C. 355(c)(3)(E), 355(j)(5)(B)(iv), 355(j)(5)(F), 
15
360cc, 355a, 355f), or prohibitions on the submis-
16
sion or licensing of biologics license applications 
17
under section 351(k)(6) (interchangeable biological 
18
product exclusivity) or section 351(k)(7) (biological 
19
product reference product exclusivity) of the Public 
20
Health Service Act (42 U.S.C. 262(k)(6), (7)). 
21
(8) SUBSEQUENT
FILER.—The term ‘‘subse-
22
quent filer’’ means— 
23
(A) in the case of a drug, a party that 
24
owns or controls an abbreviated new drug appli-
25
04:40 May 29, 2019
H2700
20 
•HR 2700 IH
cation submitted pursuant to section 505(j) of 
1
the Federal Food, Drug, and Cosmetic Act (21 
2
U.S.C. 355(j)) or a new drug application sub-
3
mitted pursuant to section 505(b)(2) of the 
4
Federal 
Food, 
Drug, 
and 
Cosmetic 
Act 
5
(21U.S.C. 355(b)(2)) and filed under section 
6
505(b)(1) of such Act (21 U.S.C. 355(b)(1)) or 
7
has the exclusive rights to distribute the cov-
8
ered product that is the subject of such applica-
9
tion; or 
10
(B) in the case of a biological product, a 
11
party that owns or controls an application filed 
12
with the Food and Drug Administration under 
13
section 351(k) of the Public Health Service Act 
14
(42 U.S.C. 262(k)) or has the exclusive rights 
15
to distribute the biological product that is the 
16
subject of such application. 
17
(h) EFFECTIVE DATE.—This section applies with re-
18
spect to agreements described in subsection (a) entered 
19
into on or after the date of the enactment of this Act. 
20
SEC. 112. NOTICE AND CERTIFICATION OF AGREEMENTS. 
21
(a) NOTICE OF ALL AGREEMENTS.—Section 1111(7) 
22
of the Medicare Prescription Drug, Improvement, and 
23
Modernization Act of 2003 (21 U.S.C. 355 note) is 
24
amended by inserting ‘‘or the owner of a patent for which 
25
04:40 May 29, 2019
H2700
21 
•HR 2700 IH
a claim of infringement could reasonably be asserted 
1
against any person for making, using, offering to sell, sell-
2
ing, or importing into the United States a biological prod-
3
uct that is the subject of a biosimilar biological product 
4
application’’ before the period at the end. 
5
(b) CERTIFICATION OF AGREEMENTS.—Section 1112 
6
of such Act (21 U.S.C. 355 note) is amended by adding 
7
at the end the following: 
8
‘‘(d) CERTIFICATION.—The Chief Executive Officer 
9
or the company official responsible for negotiating any 
10
agreement under subsection (a) or (b) that is required to 
11
be filed under subsection (c) shall, within 30 days of such 
12
filing, execute and file with the Assistant Attorney General 
13
and the Commission a certification as follows: ‘I declare 
14
that the following is true, correct, and complete to the best 
15
of my knowledge: The materials filed with the Federal 
16
Trade Commission and the Department of Justice under 
17
section 1112 of the Medicare Prescription Drug, Improve-
18
ment, and Modernization Act of 2003, with respect to the 
19
agreement referenced in this certification— 
20
‘‘ ‘(1) represent the complete, final, and exclu-
21
sive agreement between the parties; 
22
‘‘ ‘(2) include any ancillary agreements that are 
23
contingent upon, provide a contingent condition for, 
24
04:40 May 29, 2019
H2700
22 
•HR 2700 IH
were entered into within 30 days of, or are otherwise 
1
related to, the referenced agreement; and 
2
‘‘ ‘(3) include written descriptions of any oral 
3
agreements, representations, commitments, or prom-
4
ises between the parties that are responsive to sub-
5
section (a) or (b) of such section 1112 and have not 
6
been reduced to writing.’.’’. 
7
SEC. 113. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
8
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
9
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
10
is amended by inserting ‘‘section 111 of the Lowering Pre-
11
scription Drug Costs and Extending Community Health 
12
Centers and Other Public Health Priorities Act or’’ after 
13
‘‘that the agreement has violated’’. 
14
SEC. 114. COMMISSION LITIGATION AUTHORITY. 
15
Section 16(a)(2) of the Federal Trade Commission 
16
Act (15 U.S.C. 56(a)(2)) is amended— 
17
(1) in subparagraph (D), by striking ‘‘or’’ after 
18
the semicolon; 
19
(2) in subparagraph (E), by inserting ‘‘or’’ 
20
after the semicolon; and 
21
(3) by inserting after subparagraph (E) the fol-
22
lowing: 
23
‘‘(F) under section 111(d)(3)(A) of the 
24
Lowering Prescription Drug Costs and Extend-
25
04:40 May 29, 2019
H2700
23 
•HR 2700 IH
ing Community Health Centers and Other Pub-
1
lic Health Priorities Act;’’. 
2
SEC. 115. STATUTE OF LIMITATIONS. 
3
(a) IN GENERAL.—Except as provided in subsection 
4
(b), the Commission shall commence any administrative 
5
proceeding or civil action to enforce section 111 of this 
6
Act not later than 6 years after the date on which the 
7
parties to the agreement file the Notice of Agreement as 
8
provided by section 1112(c)(2) and (d) of the Medicare 
9
Prescription Drug, Improvement, and Modernization Act 
10
of 2003 (21 U.S.C. 355 note). 
11
(b) CIVIL ACTION AFTER ISSUANCE OF CEASE AND 
12
DESIST ORDER.—If the Commission has issued a cease 
13
and desist order under section 5 of the Federal Trade 
14
Commission Act (15 U.S.C. 45) for violation of section 
15
111 of this Act and the proceeding for the issuance of 
16
such order was commenced within the period required by 
17
subsection (a) of this section, such subsection does not 
18
prohibit the commencement, after such period, of a civil 
19
action under section 111(d)(3)(A) against a party to such 
20
order or a civil action under subsection (l) of such section 
21
5 for violation of such order. 
22
04:40 May 29, 2019
H2700
24 
•HR 2700 IH
Subtitle C—Creating and Restoring 
1
Equal 
Access 
to 
Equivalent 
2
Samples 
3
SEC. 121. ACTIONS FOR DELAYS OF GENERIC DRUGS AND 
4
BIOSIMILAR BIOLOGICAL PRODUCTS. 
5
(a) DEFINITIONS.—In this section— 
6
(1) the term ‘‘commercially reasonable, market- 
7
based terms’’ means— 
8
(A) a nondiscriminatory price for the sale 
9
of the covered product at or below, but not 
10
greater than, the most recent wholesale acquisi-
11
tion cost for the drug, as defined in section 
12
1847A(c)(6)(B) of the Social Security Act (42 
13
U.S.C. 1395w–3a(c)(6)(B)); 
14
(B) a schedule for delivery that results in 
15
the transfer of the covered product to the eligi-
16
ble product developer consistent with the timing 
17
under subsection (b)(2)(A)(iv); and 
18
(C) no additional conditions are imposed 
19
on the sale of the covered product; 
20
(2) the term ‘‘covered product’’— 
21
(A) means— 
22
(i) any drug approved under sub-
23
section (c) or (j) of section 505 of the Fed-
24
eral Food, Drug, and Cosmetic Act (21 
25
04:40 May 29, 2019
H2700
25 
•HR 2700 IH
U.S.C. 355) or biological product licensed 
1
under subsection (a) or (k) of section 351 
2
of the Public Health Service Act (42 
3
U.S.C. 262); 
4
(ii) any combination of a drug or bio-
5
logical product described in clause (i); or 
6
(iii) when reasonably necessary to 
7
support approval of an application under 
8
section 505 of the Federal Food, Drug, 
9
and Cosmetic Act (21 U.S.C. 355), or sec-
10
tion 351 of the Public Health Service Act 
11
(42 U.S.C. 262), as applicable, or other-
12
wise meet the requirements for approval 
13
under either such section, any product, in-
14
cluding any device, that is marketed or in-
15
tended for use with such a drug or biologi-
16
cal product; and 
17
(B) does not include any drug or biological 
18
product that appears on the drug shortage list 
19
in effect under section 506E of the Federal 
20
Food, Drug, and Cosmetic Act (21 U.S.C. 
21
356e), unless— 
22
(i) the drug or biological product has 
23
been on the drug shortage list in effect 
24
04:40 May 29, 2019
H2700
26 
•HR 2700 IH
under such section 506E continuously for 
1
more than 6 months; or 
2
(ii) the Secretary determines that in-
3
clusion of the drug or biological product as 
4
a covered product is likely to contribute to 
5
alleviating or preventing a shortage. 
6
(3) the term ‘‘device’’ has the meaning given 
7
the term in section 201 of the Federal Food, Drug, 
8
and Cosmetic Act (21 U.S.C. 321); 
9
(4) the term ‘‘eligible product developer’’ means 
10
a person that seeks to develop a product for ap-
11
proval pursuant to an application for approval under 
12
subsection (b)(2) or (j) of section 505 of the Federal 
13
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or 
14
for licensing pursuant to an application under sec-
15
tion 351(k) of the Public Health Service Act (42 
16
U.S.C. 262(k)); 
17
(5) the term ‘‘license holder’’ means the holder 
18
of an application approved under subsection (c) or 
19
(j) of section 505 of the Federal Food, Drug, and 
20
Cosmetic Act (21 U.S.C. 355) or the holder of a li-
21
cense under subsection (a) or (k) of section 351 of 
22
the Public Health Service Act (42 U.S.C. 262) for 
23
a covered product; 
24
04:40 May 29, 2019
H2700
27 
•HR 2700 IH
(6) the term ‘‘REMS’’ means a risk evaluation 
1
and mitigation strategy under section 505–1 of the 
2
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
3
355–1); 
4
(7) the term ‘‘REMS with ETASU’’ means a 
5
REMS that contains elements to assure safe use 
6
under section 505–1(f) of the Federal Food, Drug, 
7
and Cosmetic Act (21 U.S.C. 355–1(f)); 
8
(8) the term ‘‘Secretary’’ means the Secretary 
9
of Health and Human Services; 
10
(9) the term ‘‘single, shared system of elements 
11
to assure safe use’’ means a single, shared system 
12
of elements to assure safe use under section 505– 
13
1(f) of the Federal Food, Drug, and Cosmetic Act 
14
(21 U.S.C. 355–1(f)); and 
15
(10) the term ‘‘sufficient quantities’’ means an 
16
amount of a covered product that the eligible prod-
17
uct developer determines allows it to— 
18
(A) conduct testing to support an applica-
19
tion under— 
20
(i) subsection (b)(2) or (j) of section 
21
505 of the Federal Food, Drug, and Cos-
22
metic Act (21 U.S.C. 355); or 
23
04:40 May 29, 2019
H2700
28 
•HR 2700 IH
(ii) section 351(k) of the Public 
1
Health Service Act (42 U.S.C. 262(k)); 
2
and 
3
(B) fulfill any regulatory requirements re-
4
lating to approval of such an application. 
5
(b) CIVIL ACTION FOR FAILURE TO PROVIDE SUFFI-
6
CIENT QUANTITIES OF A COVERED PRODUCT.— 
7
(1) IN GENERAL.—An eligible product developer 
8
may bring a civil action against the license holder 
9
for a covered product seeking relief under this sub-
10
section in an appropriate district court of the United 
11
States alleging that the license holder has declined 
12
to provide sufficient quantities of the covered prod-
13
uct to the eligible product developer on commercially 
14
reasonable, market-based terms. 
15
(2) ELEMENTS.— 
16
(A) IN GENERAL.—To prevail in a civil ac-
17
tion brought under paragraph (1), an eligible 
18
product developer shall prove, by a preponder-
19
ance of the evidence— 
20
(i) that— 
21
(I) the covered product is not 
22
subject to a REMS with ETASU; or 
23
(II) if the covered product is sub-
24
ject to a REMS with ETASU— 
25
04:40 May 29, 2019
H2700
29 
•HR 2700 IH
(aa) the eligible product de-
1
veloper has obtained a covered 
2
product authorization from the 
3
Secretary in accordance with sub-
4
paragraph (B); and 
5
(bb) the eligible product de-
6
veloper has provided a copy of 
7
the covered product authorization 
8
to the license holder; 
9
(ii) that, as of the date on which the 
10
civil action is filed, the product developer 
11
has not obtained sufficient quantities of 
12
the covered product on commercially rea-
13
sonable, market-based terms; 
14
(iii) that the eligible product developer 
15
has submitted a written request to pur-
16
chase sufficient quantities of the covered 
17
product to the license holder and such re-
18
quest— 
19
(I) was sent to a named cor-
20
porate officer of the license holder; 
21
(II) was made by certified or reg-
22
istered mail with return receipt re-
23
quested; 
24
04:40 May 29, 2019
H2700
30 
•HR 2700 IH
(III) specified an individual as 
1
the point of contact for the license 
2
holder to direct communications re-
3
lated to the sale of the covered prod-
4
uct to the eligible product developer 
5
and a means for electronic and writ-
6
ten communications with that indi-
7
vidual; and 
8
(IV) specified an address to 
9
which the covered product was to be 
10
shipped upon reaching an agreement 
11
to transfer the covered product; and 
12
(iv) that the license holder has not de-
13
livered to the eligible product developer 
14
sufficient quantities of the covered product 
15
on commercially reasonable, market-based 
16
terms— 
17
(I) for a covered product that is 
18
not subject to a REMS with ETASU, 
19
by the date that is 31 days after the 
20
date on which the license holder re-
21
ceived the request for the covered 
22
product; and 
23
04:40 May 29, 2019
H2700
31 
•HR 2700 IH
(II) for a covered product that is 
1
subject to a REMS with ETASU, by 
2
31 days after the later of— 
3
(aa) the date on which the 
4
license holder received the re-
5
quest for the covered product; or 
6
(bb) the date on which the 
7
license holder received a copy of 
8
the covered product authorization 
9
issued by the Secretary in ac-
10
cordance with subparagraph (B). 
11
(B) AUTHORIZATION FOR COVERED PROD-
12
UCT SUBJECT TO A REMS WITH ETASU.— 
13
(i) REQUEST.—An eligible product de-
14
veloper may submit to the Secretary a 
15
written request for the eligible product de-
16
veloper to be authorized to obtain suffi-
17
cient quantities of an individual covered 
18
product subject to a REMS with ETASU. 
19
(ii) AUTHORIZATION.—Not later than 
20
120 days after the date on which a request 
21
under clause (i) is received, the Secretary 
22
shall, by written notice, authorize the eligi-
23
ble product developer to obtain sufficient 
24
quantities of an individual covered product 
25
04:40 May 29, 2019
H2700
32 
•HR 2700 IH
subject to a REMS with ETASU for pur-
1
poses of— 
2
(I) development and testing that 
3
does not involve human clinical trials, 
4
if the eligible product developer has 
5
agreed to comply with any conditions 
6
the Secretary determines necessary; or 
7
(II) development and testing that 
8
involves human clinical trials, if the 
9
eligible product developer has— 
10
(aa)(AA) submitted proto-
11
cols, 
informed 
consent 
docu-
12
ments, and informational mate-
13
rials for testing that include pro-
14
tections that provide safety pro-
15
tections comparable to those pro-
16
vided by the REMS for the cov-
17
ered product; or 
18
(BB) otherwise satisfied the 
19
Secretary that such protections 
20
will be provided; and 
21
(bb) met any other require-
22
ments the Secretary may estab-
23
lish. 
24
04:40 May 29, 2019
H2700
33 
•HR 2700 IH
(iii) NOTICE.—A covered product au-
1
thorization issued under this subparagraph 
2
shall state that the provision of the covered 
3
product by the license holder under the 
4
terms of the authorization will not be a 
5
violation of the REMS for the covered 
6
product. 
7
(3) AFFIRMATIVE DEFENSE.—In a civil action 
8
brought under paragraph (1), it shall be an affirma-
9
tive defense, on which the defendant has the burden 
10
of persuasion by a preponderance of the evidence— 
11
(A) that, on the date on which the eligible 
12
product developer requested to purchase suffi-
13
cient quantities of the covered product from the 
14
license holder— 
15
(i) neither the license holder nor any 
16
of its agents, wholesalers, or distributors 
17
was engaged in the manufacturing or com-
18
mercial marketing of the covered product; 
19
and 
20
(ii) neither the license holder nor any 
21
of its agents, wholesalers, or distributors 
22
otherwise had access to inventory of the 
23
covered product to supply to the eligible 
24
04:40 May 29, 2019
H2700
34 
•HR 2700 IH
product developer on commercially reason-
1
able, market-based terms; 
2
(B) that— 
3
(i) the license holder sells the covered 
4
product through agents, distributors, or 
5
wholesalers; 
6
(ii) the license holder has placed no 
7
restrictions, explicit or implicit, on its 
8
agents, distributors, or wholesalers to sell 
9
covered products to eligible product devel-
10
opers; and 
11
(iii) the covered product can be pur-
12
chased by the eligible product developer in 
13
sufficient quantities on commercially rea-
14
sonable, market-based terms from the 
15
agents, distributors, or wholesalers of the 
16
license holder; or 
17
(C) that the license holder made an offer 
18
to the individual specified pursuant to para-
19
graph (2)(A)(iii)(III), by a means of commu-
20
nication (electronic, written, or both) specified 
21
pursuant to such paragraph, to sell sufficient 
22
quantities of the covered product to the eligible 
23
product developer at commercially reasonable 
24
market-based terms— 
25
04:40 May 29, 2019
H2700
35 
•HR 2700 IH
(i) for a covered product that is not 
1
subject to a REMS with ETASU, by the 
2
date that is 14 days after the date on 
3
which the license holder received the re-
4
quest for the covered product, and the eli-
5
gible product developer did not accept such 
6
offer by the date that is 7 days after the 
7
date on which the eligible product devel-
8
oper received such offer from the license 
9
holder; or 
10
(ii) for a covered product that is sub-
11
ject to a REMS with ETASU, by the date 
12
that is 20 days after the date on which the 
13
license holder received the request for the 
14
covered product, and the eligible product 
15
developer did not accept such offer by the 
16
date that is 10 days after the date on 
17
which the eligible product developer re-
18
ceived such offer from the license holder. 
19
(4) REMEDIES.— 
20
(A) IN GENERAL.—If an eligible product 
21
developer prevails in a civil action brought 
22
under paragraph (1), the court shall— 
23
(i) order the license holder to provide 
24
to the eligible product developer without 
25
04:40 May 29, 2019
H2700
36 
•HR 2700 IH
delay sufficient quantities of the covered 
1
product on commercially reasonable, mar-
2
ket-based terms; 
3
(ii) award to the eligible product de-
4
veloper reasonable attorney’s fees and costs 
5
of the civil action; and 
6
(iii) award to the eligible product de-
7
veloper a monetary amount sufficient to 
8
deter the license holder from failing to pro-
9
vide eligible product developers with suffi-
10
cient quantities of a covered product on 
11
commercially 
reasonable, 
market-based 
12
terms, if the court finds, by a preponder-
13
ance of the evidence— 
14
(I) that the license holder delayed 
15
providing sufficient quantities of the 
16
covered product to the eligible product 
17
developer without a legitimate busi-
18
ness justification; or 
19
(II) that the license holder failed 
20
to comply with an order issued under 
21
clause (i). 
22
(B) MAXIMUM
MONETARY
AMOUNT.—A 
23
monetary amount awarded under subparagraph 
24
(A)(iii) shall not be greater than the revenue 
25
04:40 May 29, 2019
H2700
37 
•HR 2700 IH
that the license holder earned on the covered 
1
product during the period— 
2
(i) beginning on— 
3
(I) for a covered product that is 
4
not subject to a REMS with ETASU, 
5
the date that is 31 days after the date 
6
on which the license holder received 
7
the request; or 
8
(II) for a covered product that is 
9
subject to a REMS with ETASU, the 
10
date that is 31 days after the later 
11
of— 
12
(aa) the date on which the 
13
license holder received the re-
14
quest; or 
15
(bb) the date on which the 
16
license holder received a copy of 
17
the covered product authorization 
18
issued by the Secretary in ac-
19
cordance with paragraph (2)(B); 
20
and 
21
(ii) ending on the date on which the 
22
eligible product developer received suffi-
23
cient quantities of the covered product. 
24
04:40 May 29, 2019
H2700
38 
•HR 2700 IH
(C) AVOIDANCE
OF
DELAY.—The court 
1
may issue an order under subparagraph (A)(i) 
2
before conducting further proceedings that may 
3
be necessary to determine whether the eligible 
4
product developer is entitled to an award under 
5
clause (ii) or (iii) of subparagraph (A), or the 
6
amount of any such award. 
7
(c) LIMITATION OF LIABILITY.—A license holder for 
8
a covered product shall not be liable for any claim under 
9
Federal, State, or local law arising out of the failure of 
10
an eligible product developer to follow adequate safeguards 
11
to assure safe use of the covered product during develop-
12
ment or testing activities described in this section, includ-
13
ing transportation, handling, use, or disposal of the cov-
14
ered product by the eligible product developer. 
15
(d) NO VIOLATION OF REMS.—Section 505–1 of the 
16
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355– 
17
1) is amended by adding at the end the following new sub-
18
section: 
19
‘‘(l) PROVISION OF SAMPLES NOT A VIOLATION OF 
20
STRATEGY.—The provision of samples of a covered prod-
21
uct to an eligible product developer (as those terms are 
22
defined in section 121(a) of the Lowering Prescription 
23
Drug Costs and Extending Community Health Centers 
24
and Other Public Health Priorities Act) shall not be con-
25
04:40 May 29, 2019
H2700
39 
•HR 2700 IH
sidered a violation of the requirements of any risk evalua-
1
tion and mitigation strategy that may be in place under 
2
this section for such drug.’’. 
3
(e) RULE OF CONSTRUCTION.— 
4
(1) DEFINITION.—In this subsection, the term 
5
‘‘antitrust laws’’— 
6
(A) has the meaning given the term in 
7
subsection (a) of the first section of the Clayton 
8
Act (15 U.S.C. 12); and 
9
(B) includes section 5 of the Federal 
10
Trade Commission Act (15 U.S.C. 45) to the 
11
extent that such section applies to unfair meth-
12
ods of competition. 
13
(2) ANTITRUST LAWS.—Nothing in this section 
14
shall be construed to limit the operation of any pro-
15
vision of the antitrust laws. 
16
SEC. 122. REMS APPROVAL PROCESS FOR SUBSEQUENT 
17
FILERS. 
18
Section 505–1 of the Federal Food, Drug, and Cos-
19
metic Act (21 U.S.C. 355–1), as amended by section 121, 
20
is further amended— 
21
(1) in subsection (g)(4)(B)— 
22
(A) in clause (i) by striking ‘‘or’’ after the 
23
semicolon; 
24
04:40 May 29, 2019
H2700
40 
•HR 2700 IH
(B) in clause (ii) by striking the period at 
1
the end and inserting ‘‘; or’’; and 
2
(C) by adding at the end the following: 
3
‘‘(iii) accommodate different, com-
4
parable aspects of the elements to assure 
5
safe use for a drug that is the subject of 
6
an application under section 505(j), and 
7
the applicable listed drug.’’; 
8
(2) in subsection (i)(1), by striking subpara-
9
graph (C) and inserting the following: 
10
‘‘(C)(i) Elements to assure safe use, if re-
11
quired under subsection (f) for the listed drug, 
12
which, subject to clause (ii), for a drug that is 
13
the subject of an application under section 
14
505(j) may use— 
15
‘‘(I) a single, shared system with the 
16
listed drug under subsection (f); or 
17
‘‘(II) a different, comparable aspect of 
18
the elements to assure safe use under sub-
19
section (f). 
20
‘‘(ii) The Secretary may require a drug 
21
that is the subject of an application under sec-
22
tion 505(j) and the listed drug to use a single, 
23
shared system under subsection (f), if the Sec-
24
retary determines that no different, comparable 
25
04:40 May 29, 2019
H2700
41 
•HR 2700 IH
aspect of the elements to assure safe use could 
1
satisfy the requirements of subsection (f).’’; 
2
(3) in subsection (i), by adding at the end the 
3
following: 
4
‘‘(3) SHARED
REMS.—If the Secretary ap-
5
proves, in accordance with paragraph (1)(C)(i)(II), a 
6
different, comparable aspect of the elements to as-
7
sure safe use under subsection (f) for a drug that 
8
is the subject of an abbreviated new drug application 
9
under section 505(j), the Secretary may require that 
10
such different comparable aspect of the elements to 
11
assure safe use can be used with respect to any 
12
other drug that is the subject of an application 
13
under section 505(j) or 505(b) that references the 
14
same listed drug.’’; and 
15
(4) by adding at the end the following: 
16
‘‘(m) SEPARATE REMS.—When used in this section, 
17
the terms ‘different, comparable aspect of the elements to 
18
assure safe use’ or ‘different, comparable approved risk 
19
evaluation and mitigation strategies’ means a risk evalua-
20
tion and mitigation strategy for a drug that is the subject 
21
of an application under section 505(j) that uses different 
22
methods or operational means than the strategy required 
23
under subsection (a) for the applicable listed drug, or 
24
other application under section 505(j) with the same such 
25
04:40 May 29, 2019
H2700
42 
•HR 2700 IH
listed drug, but achieves the same level of safety as such 
1
strategy.’’. 
2
SEC. 123. RULE OF CONSTRUCTION. 
3
(a) IN GENERAL.—Nothing in this subtitle, the 
4
amendments made by this subtitle, or in section 505–1 
5
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
6
355–1), shall be construed as— 
7
(1) prohibiting a license holder from providing 
8
an eligible product developer access to a covered 
9
product in the absence of an authorization under 
10
this subtitle; or 
11
(2) in any way negating the applicability of a 
12
REMS with ETASU, as otherwise required under 
13
such section 505–1, with respect to such covered 
14
product. 
15
(b) DEFINITIONS.—In this section, the terms ‘‘cov-
16
ered product’’, ‘‘eligible product developer’’, ‘‘license hold-
17
er’’, and ‘‘REMS with ETASU’’ have the meanings given 
18
such terms in section 121(a). 
19
04:40 May 29, 2019
H2700
43 
•HR 2700 IH
TITLE II—EXTENSION OF 
1
PUBLIC HEALTH PROGRAMS 
2
SEC. 201. EXTENSION FOR COMMUNITY HEALTH CENTERS, 
3
THE NATIONAL HEALTH SERVICE CORPS, 
4
AND TEACHING HEALTH CENTERS THAT OP-
5
ERATE GME PROGRAMS. 
6
(a) COMMUNITY HEALTH CENTERS FUNDING.—Sec-
7
tion 10503(b)(1)(F) of the Patient Protection and Afford-
8
able Care Act (42 U.S.C. 254b–2(b)(1)(F)) is amended 
9
by striking ‘‘fiscal year 2019’’ and inserting ‘‘each of fiscal 
10
years 2019 and 2020’’. 
11
(b) NATIONAL HEALTH SERVICE CORPS.—Section 
12
10503(b)(2)(F) of the Patient Protection and Affordable 
13
Care Act (42 U.S.C. 254b–2(b)(2)(F)) is amended by 
14
striking ‘‘2018 and 2019’’ and inserting ‘‘2018, 2019, and 
15
2020’’. 
16
(c) TEACHING HEALTH CENTERS THAT OPERATE 
17
GRADUATE MEDICAL EDUCATION PROGRAMS.—Section 
18
340H(g)(1) of the Public Health Service Act (42 U.S.C. 
19
256h(g)(1)) is amended by striking ‘‘2018 and 2019’’ and 
20
inserting ‘‘2018, 2019, and 2020’’. 
21
(d) APPLICATION.—Amounts appropriated pursuant 
22
to this section for fiscal year 2020 are subject to the re-
23
quirements contained in Public Law 115–245 for funds 
24
04:40 May 29, 2019
H2700
44 
•HR 2700 IH
for programs authorized under sections 330 through 340 
1
of the Public Health Service Act (42 U.S.C. 254b–256). 
2
(e) CONFORMING AMENDMENT.—Section 3014(h)(4) 
3
of title 18, United States Code, is amended by striking 
4
‘‘and section 50901(e) of the Advancing Chronic Care, Ex-
5
tenders, and Social Services Act’’ and inserting ‘‘, section 
6
50901(e) of the Advancing Chronic Care, Extenders, and 
7
Social Services Act, and section 201(d) of the Lowering 
8
Prescription Drug Costs and Extending Community 
9
Health Centers and Other Public Health Priorities Act’’. 
10
SEC. 202. EXTENSION FOR SPECIAL DIABETES PROGRAMS. 
11
(a) SPECIAL DIABETES PROGRAM FOR TYPE I DIA-
12
BETES.—Section 330B(b)(2)(D) of the Public Health 
13
Service Act (42 U.S.C. 254c–2(b)(2)(D)) is amended by 
14
striking ‘‘2018 and 2019’’ and inserting ‘‘2018, 2019, and 
15
2020’’. 
16
(b) SPECIAL DIABETES PROGRAM FOR INDIANS.— 
17
Section 330C(c)(2)(D) of the Public Health Service Act 
18
(42 U.S.C. 254c–3(c)(2)(D)) is amended by striking 
19
‘‘2018 and 2019’’ and inserting ‘‘2018, 2019, and 2020’’. 
20
SEC. 203. EXTENSION FOR FAMILY-TO-FAMILY HEALTH IN-
21
FORMATION CENTERS. 
22
(a) IN GENERAL.—Section 501(c) of the Social Secu-
23
rity Act (42 U.S.C. 701(c)(1)(A)(vii)) is amended by strik-
24
04:40 May 29, 2019
H2700
45 
•HR 2700 IH
ing ‘‘2018 and 2019’’ and inserting ‘‘2018, 2019, and 
1
2020’’. 
2
(b) CONFORMING CHANGE.—Section 501(c)(3)(C) of 
3
the Social Security Act (42 U.S.C. 701(c)(3)(C)) is 
4
amended by striking ‘‘2018 and 2019’’ and inserting 
5
‘‘2018, 2019, and 2020’’. 
6
SEC. 204. EXTENSION FOR SEXUAL RISK AVOIDANCE EDU-
7
CATION 
AND 
PERSONAL 
RESPONSIBILITY 
8
EDUCATION. 
9
(a) SEXUAL RISK AVOIDANCE EDUCATION.—Sub-
10
sections (a) and (f) of section 510 of the Social Security 
11
Act (42 U.S.C. 710) are amended by striking ‘‘2018 and 
12
2019’’ each place it appears and inserting ‘‘2018, 2019, 
13
and 2020’’. 
14
(b) PERSONAL RESPONSIBILITY EDUCATION.—Sec-
15
tion 513 of the Social Security Act (42 U.S.C. 713) is 
16
amended— 
17
(1) in subsection (a)(1)(A), by striking ‘‘2019’’ 
18
and inserting ‘‘2020’’; and 
19
(2) in subsection (a)(4), by striking ‘‘2019’’ 
20
each place it appears and inserting ‘‘2020’’; and 
21
(3) in subsection (f), by striking ‘‘2019’’ and 
22
inserting ‘‘2020’’. 
23
Æ 
04:40 May 29, 2019
H2700
